FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
A new proposal calls for federal investment to study how early microbial disruptions contribute to conditions like asthma, obesity, and allergies.
The American Lung Association’s 2023 "State of Lung Cancer" report reveals improvement in five-year survival rate across the US, including for people of color.
New RNA extraction techniques overcome barriers to help scientists better evaluate treatments for diseases such as pulmonary fibrosis.
A $20.7M federal grant will fund a 5-year inhaled vaccines initiative at the Icahn School of Medicine at Mount Sinai beginning with development of an avian influenza nasal spray prototype.
New virtual reality software from VRSim simulates emergency scene variables to prepare EMS teams for high-pressure field decisions.
Only about 18% of eligible US adults underwent lung cancer screening in 2022, lagging far behind rates for breast and colorectal cancer screenings.
Resmed announced the US introduction of its AirTouch F40, a fabric, full face CPAP mask option. It will be commercially available starting October 28, 2026.